Seeking: Fermentation technology of Pristinamycin

Inquiry:

An Asia based international company is looking for technologies in the following field:

Type of Tech Request: Licensing

Desired outcome:

Pristinamycin (CAS No：270076-60-3) is an antibiotic used primarily in the treatment of staphylococcal infections, and to a lesser extent streptococcal infections. We’re looking for a technology of Pristinamycin based on fermentation. Both of the strain and the process are included.

The technology should have over 5000u/ml fermentation titre and other competitive parameters, and not infringe on other patents and intellectual property right. It is better that it can be directly used for APIs industrial production. Details of the Technology Request:

Pristinamycin (INN) (CAS No：270076-60-3), also spelled pristinamycine, is an antibiotic used primarily in the treatment of staphylococcal infections, and to a lesser extent streptococcal infections. It is a streptogramin group antibiotic, similar to virginiamycin, derived from the bacterium Streptomyces pristinaespiralis. It is marketed in Europe by Sanofi-Aventis under the trade name Synercid and Pyostacine.

Pristinamycin is a mixture of two components that have a synergistic antibacterial action. Pristinamycin IA is a macrolide, and results in pristinamycin having a similar spectrum of action to erythromycin. Pristinamycin IIA (streptogramin A) is a depsipeptide.[1] PI and PII are coproduced by S. pristinaespiralis in a ratio of 30:70.

Each compound binds to the bacterial 50 S ribosomal subunit and inhibits the elongation process of the protein synthesis, thereby exhibiting only a moderate bacteriostatic activity. Clinicuse：Despite the macrolide component, it is effective against erythromycin-resistant staphylococci and strepcococci.[3][4] Importantly, it is active against methicillin-resistant Staphylococcus aureus (MRSA). Its usefulness for severe infections, however, may be limited by the lack of an intravenous formulation owing to its poor solubility.[5] Nevertheless it is sometimes used as an alternative to rifampicin+fusidic acid or linezolid for the treatment of MRSA.

We’re looking for a technology of Pristinamycin based on fermentation. Both of the strain and the process are included. The strain should have productivity of more than 5000u/ml (harvest fermentation titre). It’s better that the technology including the strain has been commercialized at industrial scale fermentor.